Clene (NASDAQ:CLNN) Posts Earnings Results, Misses Estimates By $0.05 EPS

Clene (NASDAQ:CLNN) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.05), FiscalAI reports. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million.

Clene Price Performance

NASDAQ CLNN traded up $0.28 during trading on Thursday, reaching $6.78. The company’s stock had a trading volume of 167,275 shares, compared to its average volume of 361,338. The stock has a market capitalization of $79.83 million, a PE ratio of -2.62 and a beta of 0.89. The firm has a fifty day moving average of $5.94 and a 200 day moving average of $6.39. Clene has a one year low of $2.28 and a one year high of $13.50.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CLNN shares. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Clene in a report on Monday, May 4th. Weiss Ratings upgraded Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Canaccord Genuity Group restated a “buy” rating and issued a $48.00 price objective on shares of Clene in a research note on Friday, March 13th. Finally, D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Monday, May 4th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.25.

Insiders Place Their Bets

In other news, major shareholder Chidozie Ugwumba sold 73,296 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total transaction of $454,435.20. Following the transaction, the insider directly owned 103,417 shares in the company, valued at approximately $641,185.40. This represents a 41.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 327,677 shares of company stock valued at $2,043,481. 28.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Clene

Several institutional investors and hedge funds have recently bought and sold shares of the stock. SymBiosis Capital Partners LLC purchased a new stake in Clene in the 4th quarter worth approximately $4,523,000. Scoggin Management LP lifted its holdings in Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after buying an additional 107,250 shares during the period. PEAK6 LLC purchased a new stake in Clene in the 4th quarter worth approximately $294,000. Ensign Peak Advisors Inc lifted its holdings in Clene by 668.6% in the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after buying an additional 99,481 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after buying an additional 6,090 shares during the period. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).